GeoVax Labs, Inc. New — Rendiconto Finanziario Trimestrale (NASDAQ:GOVX)

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 1.5209 M
Employee 17
Founded 1988
CEO David A. Dodd
Website www.geovax.com
Headquarter Delaware, United States
FIGI BBG000BGGJD8
Industry Technology

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

1.52 M Capitalizzazione di mercato

Rapporto prezzo/utili

-0.18

Rapporto prezzo/fatturato

1.32

GeoVax Labs Inc

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated.

GOVX

Financials

GeoVax Labs Inc

Notizie

D. Boral Capital declassa il rating di GeoVax Labs a Hold

D. Boral Capital downgrades GeoVax Labs stock rating to Hold

Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - Aclarion (NASDAQ:ACON), AXT (NASDAQ:AXTI)

Dow Gains Over 200 Points; Conagra Shares Fall After Q2 Results - Autozi Internet Tech (NASDAQ:AZI), Conagra Brands (NYSE:CAG)

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

GeoVax alla Emerging Growth Conference: Promettente vaccino per immunocompromessi

GeoVax at Emerging Growth Conference: Vaccine Promise for Immunocompromised

GeoVax Labs at H.C. Wainwright: Strategic Focus on Vaccine Innovation

GeoVax Labs at Emerging Growth Conference 85: Strategic Vaccine Developments

GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?

GeoVax Labs receives Nasdaq notice for non-compliance with minimum bid price

GeoVax Labs Revenue Doubles in Q2